Quantcast

Latest Telik Inc. Stories

2009-05-21 15:05:00

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL. Details of the presentation are as follows: -- Abstract #5552 - General Poster...

2009-05-07 15:05:00

PALO ALTO, Calif., May 7 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2009. The net loss for the quarter ended March 31, 2009, was $7.7 million, or $0.14 per share, compared with a net loss of $9.8 million, or $0.19 per share, for the same period in 2008. As of March 31, 2009, cash, cash equivalents, restricted cash and investments totaled $57.3 million, compared with $63.5 million for the quarter ended...

2009-04-28 17:33:00

PALO ALTO, Calif., April 28 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced results of studies on two of its drug development programs that were presented at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver, CO. The abstracts can be found on the Telik website, www.telik.com. In vivo Characterization and Mechanism of Action of Orally Active Aurora Kinase/ VEGFR Inhibitors; Abstract # 1764 Aurora kinases are Ser/Thr kinases that play an...

2009-04-14 19:27:00

PALO ALTO, Calif., April 14 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that two abstracts highlighting results from its Research and Development programs will be presented at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver, CO. Details of the presentations are as follows: In vivo Characterization and Mechanism of Action of Orally Active Aurora Kinase/VEGFR Inhibitors; Sunday, April 19, 2009, 1:00 - 5:00pm; Kinase...

2009-02-26 15:08:00

PALO ALTO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $0.4 million, or $0.01 per share, for the three months ended December 31, 2008, compared with a net loss of $12.9 million, or $0.25 per share, for the same period in 2007. For the twelve months ended December 31, 2008, Telik reported a net loss of $31.8 million, or $0.60 per share, compared with a net loss of $55.2 million, or $1.05 per share, for the year ended December 31, 2007. The...

2009-02-19 15:03:00

PALO ALTO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that its year-end conference call and webcast will be held on Thursday, February 26, 2009 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the fourth quarter and year ended December 31, 2008. The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-288-8974 or...

2009-02-11 16:00:00

PALO ALTO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that it is implementing a reorganization to focus on its most advanced preclinical and clinical drug development programs. The reorganization will enable the company to continue the development of TELINTRA(R) and the two leading preclinical drug candidates: a prodrug cytotoxic, TLK58747, and dual Aurora-VEGFR kinase inhibitor, TLK60404. The restructuring will involve a workforce reduction of...

2008-10-29 18:00:06

PALO ALTO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Telik, Inc. today announced top-line results from an interrupted Phase 3 randomized study of Telcyta (canfosfamide HCL) in combination with pegylated liposomal doxorubicin (PLD) versus PLD alone in second-line therapy in platinum refractory, primary platinum resistant or secondary platinum resistant ovarian cancer (definitions of platinum status are provided below). On an intent-to-treat (ITT) basis for the 125 enrolled patients, the...

2008-08-21 18:00:53

PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc. announced today that the lead compounds of its Aurora kinase and VEGFR dual inhibitor program met a significant development milestone. Aurora kinase is a critical signaling enzyme whose function is required for cancer cell division, while vascular endothelial growth factor receptor (VEGFR) plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. Telik's lead compounds...

2008-08-19 09:01:12

PALO ALTO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Telik, Inc. announced today that it has entered into a license agreement with ReceptorBio, Inc. which would enable ReceptorBio to develop and commercialize Telik's oral small molecule insulin receptor activators. These compounds were identified through the application of TRAP(R), Telik's proprietary drug discovery technology. The agreement provides for payments related to regulatory milestones and royalties based on product sales....


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related